Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biopharmaceuticals safety perception in Slovakia: considerations and real-life pharmacovigilance data.

Bratislavske lekarske listy·2021
Same author

Risk perception of NSAIDs in South Dakota in comparison with Slovakia and Greece.

Bratislavske lekarske listy·2020
Same author

Drug usage analysis in pregnant women.

Bratislavske lekarske listy·2019
Same author

Risk perception of NSAIDs in hospitalized patients in Greece.

Bratislavske lekarske listy·2017
Same author

Waldenstrom macroglobulinemia cells devoid of BTK<sup>C481S</sup> or CXCR4<sup>WHIM-like</sup> mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.

Blood cancer journal·2017
Same author

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.

Blood cancer journal·2016

Related Experiment Video

Updated: May 24, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

A commentary on a decrease in consumption of selective COX-2 inhibitors (coxibs) Comparison between Slovakia and

R Hudec1, M Kriska, J Tisonova

  • 1Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. dr.hudec@gmail.com

Bratislavske Lekarske Listy
|March 3, 2012
PubMed
Summary
This summary is machine-generated.

Slovak coxib consumption remained low, decreasing after 2004, unlike Nordic countries. Medical professionals perceived coxibs as safe analgesics despite noted cardiovascular risks.

More Related Videos

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
12:44

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs

Published on: January 27, 2023

Related Experiment Videos

Last Updated: May 24, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
12:44

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs

Published on: January 27, 2023

Area of Science:

  • Pharmacoeconomics
  • Drug Utilization Studies
  • Cardiovascular Risk Assessment

Background:

  • Coxibs, a class of non-steroidal anti-inflammatory drugs (NSAIDs), emerged with novel mechanisms.
  • Concerns regarding cardiovascular thrombotic events, particularly with rofecoxib, influenced prescribing patterns.
  • Understanding regional utilization and risk perception is crucial for informed drug policy.

Purpose of the Study:

  • To analyze coxib utilization trends in Slovakia and compare them with Nordic countries (Denmark, Finland, Norway).
  • To assess the perception of coxib safety among general practitioners.
  • To identify factors influencing coxib prescription patterns.

Main Methods:

  • Analysis of coxib consumption data in Slovakia (1999-2009) from the State Institute for Drug Control.
  • Comparison of Slovak data with annual health statistics from Denmark, Finland, and Norway.
  • Survey of General Practitioners regarding perceived coxib risk and safety.

Main Results:

  • Coxib consumption in Slovakia initially increased but markedly decreased after 2004.
  • Slovak coxib utilization was significantly lower (1.44% of NSAIDs in 2003) compared to Norway (41.2%).
  • 14% of surveyed General Practitioners considered coxibs the safest analgesic option.

Conclusions:

  • Published data indicate a significant decline in coxib consumption following safety concerns.
  • Substantial differences (p<0.001) in coxib utilization were observed between Slovakia and Nordic countries from 1999-2009.
  • Low Slovak utilization may be attributed to factors like new drug introduction, higher prices, and established prescribing habits.